Two new compounds have been isolated from the leaves of Hypericum styphelioides. Their structures have been established on the basis of mass spectrometry and 2D NMR techniques as 1,3,5-trihydroxy-2-(2',2'-dimethyl-4'-isopropenyl)cyclopentanylxanthone (1) and 3,5-dihydroxybenzophenon-4-beta-d-glucoside (2). Known compounds 5-O-demethylpaxanthonin (3) and 3-geranyl-1-(3-methylbutanoyl)phloroglucinol (4) were also isolated and characterized. Compounds 1-4 were evaluated for their antioxidative properties in Trolox equivalent antioxidant activity (TEAC) and chemiluminescence (CL) assays.

Deficiency of lymphocyte activation gene-3 (LAG3) is significantly associated with increased cardiovascular disease risk with in vitro results demonstrating increased TNF-α and decreased IL-10 secretion from LAG3-deficient human B lymphoblasts. The hypothesis tested in this study was that Lag3 deficiency in dendritic cells (DCs) would significantly affect cytokine expression, alter cellular metabolism, and prime naive T cells to greater effector differentiation. Experimental approaches used included differentiation of murine bone marrow–derived DCs (BMDCs) to measure secreted cytokines, cellular metabolism, RNA sequencing, whole cell proteomics, adoptive OT-II CD4+Lag3+/+ donor cells into wild-type (WT) C57BL/6 and Lag3−/− recipient mice, and ex vivo measurements of IFN-γ from cultured splenocytes. Results showed that Lag3−/− BMDCs secreted more TNF-α, were more glycolytic, used fewer fatty acids for mitochondrial respiration, and glycolysis was significantly reduced by exogenous IL-10 treatment. Under basal conditions, RNA sequencing revealed increased expression of CD40 and CD86 and other cytokine-signaling targets as compared with WT. Whole cell proteomics identified a significant number of proteins up- and downregulated in Lag3−/− BMDCs, with significant differences noted in exogenous IL-10 responsiveness compared with WT cells. Ex vivo, IFN-γ expression was significantly higher in Lag3−/− mice as compared with WT. With in vivo adoptive T cell and in vitro BMDC:T coculture experiments, Lag3−/− BMDCs showed greater T cell effector differentiation and proliferation, respectively, compared with WT BMDCs. In conclusion, Lag3 deficiency in DCs is associated with an inflammatory phenotype that provides a plausible mechanism for increased cardiovascular disease risk in humans with LAG3 deficiency.

We analyzed the P2X4 receptor structure−activity relationship of a known antagonist 5, a 1,5-dihydro-2Hnaphtho[1,2-b][1,4]diazepine-2,4(3H)-dione. Following extensive modification of the reported synthetic route, 4-pyridyl 21u (MRS4719) and 6-methyl 22c (MRS4596) analogues were most potent at human (h) P2X4R (IC 50 0.503 and 1.38 μM, respectively, and selective versus hP2X1R, hP2X2/3R, hP2X3R). Thus, the naphthalene 6-, but not 7-position was amenable to substitution, and an N-phenyl ring aza-scan identified 21u with 3-fold higher activity than 5. Compounds 21u and 22c showed neuroprotective and learning-and memory-enhancing activities in a mouse middle cerebral artery occlusion (MCAO) model of ischemic stroke, with potency of 21u > 22c. 21u dose-dependently reduced infarct volume and reduced brain atrophy at 3 and 35 days post-stroke, respectively. Relevant to clinical implication, 21u also reduced ATP-induced [Ca 2+ ] i influx in primary human monocyte-derived macrophages. This study indicates the translational potential of P2X4R antagonists for treating ischemic stroke, including in aging populations.

Although Jatropha aethiopica, popularly known in Cuba as "mata diabetes", is used in salads and as a dietary supplement, its chemical composition and antidiabetic properties yet remains unclear. In this work, we evaluate the qualitative and quantitative composition of ethanolic extract (EE) and phenolic fraction (PF) of Jatropha aethiopica leaves and their hypoglycemic and hypolipidemic activity. Chemical fractionation of the ethanolic extract yielded nine compounds, which included protocatechuic acid (1), chlorogenic acid (2), caffeic acid (3), quercetin 3-O-α-l-rhamnopyranosyl-(1 → 2)-[α-l-rhamnopyranolsyl-(1 → 6)]-β-d-galactopyranoside (4), a new kaempferol 3-O-α-l-rhamnopyranosyl-(1 → 4)-[α-l-rhamnopyranolsyl-(1 → 6)]-β-d-galactopyranoside (5), kaempferol 3-O-α-l-rhamnopyranosyl-(1 → 2)-[α-l-rhamnopyranolsyl-(1 → 6)]-β-d-glucopyranoside (6), rutin (7), kaempferol 3-O-α-l-rhamnopyranosyl-(1 → 6)-β-d-glucopyranoside (8), and quercetin (9). The compounds (1, 4-7) were quantified by high-performance liquid chromatography photodiode array detection (HPLC-PDA) in both the ethanolic extract (62.65 ± 0.15 mg/g) and phenolic fraction (61.72 ± 0.23 mg/g). The results obtained show that both ethanolic extract and phenolic fraction contributed toward the improvement of glucose tolerance, which in turn led to a decline in the glucose levels. Remarkably, the ethanolic extract presented a relatively higher promising effect compared to metformin.